The Pharmaceutical Research and Manufacturers of America (PhRMA) submitted the following response to a request from Representative Greg Walden and Senator Lamar Alexander for input on modernizing the 340B drug pricing program. PhRMA is pleased to provide input on how the 340B Drug Pricing Program (340B) can be strengthened to better support our nation’s most vulnerable patients. We look forward to continuing our conversations on meaningful improvements that can be made to ensure the 340B program is overseen and operated in a way that sustains the program for the long-term so that patients more directly benefit from the discounts provided by biopharmaceutical manufacturers.